COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		1 Months Ended			12 Months Ended
	Mar. 09, 2020	Oct. 30, 2020	Sep. 30, 2020	Jun. 30, 2016	Mar. 31, 2020	Mar. 31, 2022
Contingent sales fee description				A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater.
Accrued fees						$ 270,000
Accrued interest						$ 28,000
Merger, description	Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors.		Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company
Annual Maintenance					$ 298,000
First BLA [Member]
Future payments				$ 225,000
First Phase III clinical trial [Member]
Future payments				225,000
First Phase I clinical trial [Member]
Future payments				100,000
Annual maintenance fee				$ 50,000
Alpha Holding Inc [Member]
Initial investment		$ 2,500,000
Additional investment		2,500,000
Agreement from related party		$ 5,000,000
Investment description		The investment will be in the Company’s common stock to be priced at a low of nine cents per share and a high of 10 cents per share subject to a 90 day weighted average pricing before closing. Upon completion of the $5,000,000 investment